Telix Pharmaceuticals Limited (ASX: TLX), an Australia-based biopharmaceutical company, announced on Monday that it has dosed its first patient in a phase II investigator-initiated study of TLX101 along with external beam radiation therapy (EBRT) to treat patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM).

The product is one of the company's therapeutic clinical programs and has been granted orphan drug designation in the United States and Europe. It targets L-type amino acid transporter 1 (LAT-1), characteristically over-expressed in various malignant tumours, including HGG/GBM.

Professor Josef Pichler at Kepler University Hospital in Linz, Austria is heading the IPAX-Linz study. The final outcomes of the study reported in September 2022 revealed a favourable safety profile and encouraging preliminary therapeutic impact. The company is continuing to study the benefit of TLX101 for patients in the second line (refractory) setting at this leading neuro-oncology site in Europe. It is aiming to enrol 10 patients in order to gather additional data on clinical utility. IPAX-Linz will run concurrently with IPAX-2, which is evaluating TLX101 in combination with post-surgical standard of care comprised of EBRT and temozolomide in newly diagnosed (first line) GBM patients.